Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
(LIBERTY Trial)

Recruiting in Palo Alto (17 mi)

+51 other locations

Overseen byWilliam Gray, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Cardiovascular Systems Inc

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD).

Research Team

Jihad Mustapha, MD

Principal Investigator

Advanced Cardiac & Vascular Centers

George Adams, MD

Principal Investigator

Rex Healthcare

Gary Ansel, MD

Principal Investigator

Ohio Health

William Gray, MD

Principal Investigator

Columbia University

Eligibility Criteria

Inclusion Criteria

Subject's age ≥ 18 years.

Subject presents with a Rutherford classification of 2 to 6.

Subject presents with clinical evidence of PAD requiring endovascular intervention on one or both limbs that includes a target lesion in a native vessel located within or extending into 10 cm above the medial epicondyle to the digital arteries.

See 3 more

Treatment Details

Interventions

PAD endovascular treatments (Endovascular Procedure)

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Claudication (Rutherford 2-3)Experimental Treatment1 Intervention

Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.

Group II: CLI Rutherford 6Experimental Treatment1 Intervention

Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.

Group III: CLI Rutherford 4-5Experimental Treatment1 Intervention

Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.